Marko Skelin1, Tomo Lucijanić2, Ana-Marija Liberati-Čizmek3, Sanja Majanović Klobučar4, Marko Lucijanić5, Lejsa Jakupović6, Miro Bakula3, Jelena Vučak Lončar7, Srečko Marušić2, Tomas Matić2, Željko Romić8, Jerka Dumić9, Dario Rahelić2. 1. Pharmacy Department, General Hospital Šibenik, Šibenik, Croatia. marko.skelin@bolnica-sibenik.hr. 2. Department of Endocrinology, Diabetes and Metabolic Disorders, Dubrava University Hospital, Zagreb, Croatia. 3. Department of Endocrinology, Diabetes and Metabolic Disorders, General Hospital "Sv. Duh", Zagreb, Croatia. 4. Rijeka Clinical Hospital Centre, Faculty of Medicine, Department of Endocrinology, Diabetes and Metabolic Diseases, University of Rijeka, Rijeka, Croatia. 5. Hematology Department, Dubrava University Hospital, Zagreb, Croatia. 6. Healthcare institution of community pharmacies, Slavonski Brod, Croatia. 7. Internal Medicine Department, General Hospital Zadar, Zadar, Croatia. 8. Department of Laboratory Diagnostic, Dubrava University Hospital, Zagreb, Croatia. 9. Faculty of Pharmacy and Biochemistry, Department of Biochemistry and Molecular Biology, University of Zagreb, Zagreb, Croatia.
Abstract
AIM: Hypothyroidism is a common clinical problem that is successfully treated with hormone substitutes in the form of levothyroxine (LT4). LT4 is a drug with a narrow therapeutic index and is usually administered by strict rules, standardly at least half an hour before breakfast. The aim of this study was to investigate a possible effect of different timings of administration on thyroid function status and lipid profile. METHODS: The study included patients with the diagnosis of primary hypothyroidism, which were using a stable dose of levothyroxine. They were randomized into three different groups regarding the timing of LT4 administration in a crossover fashion. Each timing regimen lasted for at least 8 weeks; timing regimen A-half an hour before breakfast; timing regimen B-an hour before the main meal of the day; timing regimen C-at bedtime (minimally 2 h after dinner). The hormones (TSH, fT3, fT4) and lipid profile (triglycerides, HDL-, LDL-, and total cholesterol) were measured before the study, at the beginning of every timing regimen and at the end of the study. RESULTS: Altogether, 84 patients finished the study. Different timings of LT4 administration were non-inferior in comparison to the standard one and between each other. Median differences in TSH level between baseline and timing regimens were: baseline vs. A = -0.017 95% C.I. (-0.400-0.192); baseline vs. B = -0.325 95% C.I. (-0.562-0.023); baseline vs. C = -0.260 95% C.I. (-0.475-0.000). There were no statistically significant differences in either TSH, fT4, or fT3 when compared between all three timing regimens of LT4 administration and the baseline. There were no statistically significant differences in any of the lipid profile parameters (triglycerides, HDL-, LDL-, and total cholesterol) when compared between all three timing regimens of LT4 administration and the baseline. CONCLUSION: The three investigated timing regimens of LT4 administration were equally efficient and offer additional options regarding the treatment individualization.
RCT Entities:
AIM: Hypothyroidism is a common clinical problem that is successfully treated with hormone substitutes in the form of levothyroxine (LT4). LT4 is a drug with a narrow therapeutic index and is usually administered by strict rules, standardly at least half an hour before breakfast. The aim of this study was to investigate a possible effect of different timings of administration on thyroid function status and lipid profile. METHODS: The study included patients with the diagnosis of primary hypothyroidism, which were using a stable dose of levothyroxine. They were randomized into three different groups regarding the timing of LT4 administration in a crossover fashion. Each timing regimen lasted for at least 8 weeks; timing regimen A-half an hour before breakfast; timing regimen B-an hour before the main meal of the day; timing regimen C-at bedtime (minimally 2 h after dinner). The hormones (TSH, fT3, fT4) and lipid profile (triglycerides, HDL-, LDL-, and total cholesterol) were measured before the study, at the beginning of every timing regimen and at the end of the study. RESULTS: Altogether, 84 patients finished the study. Different timings of LT4 administration were non-inferior in comparison to the standard one and between each other. Median differences in TSH level between baseline and timing regimens were: baseline vs. A = -0.017 95% C.I. (-0.400-0.192); baseline vs. B = -0.325 95% C.I. (-0.562-0.023); baseline vs. C = -0.260 95% C.I. (-0.475-0.000). There were no statistically significant differences in either TSH, fT4, or fT3 when compared between all three timing regimens of LT4 administration and the baseline. There were no statistically significant differences in any of the lipid profile parameters (triglycerides, HDL-, LDL-, and total cholesterol) when compared between all three timing regimens of LT4 administration and the baseline. CONCLUSION: The three investigated timing regimens of LT4 administration were equally efficient and offer additional options regarding the treatment individualization.
Entities:
Keywords:
Adherence; Hypothyroidism.; Individualization of pharmacotherapy; Levothyroxine; Timing of administration
Authors: Issac Sachmechi; David M Reich; Michael Aninyei; Francisca Wibowo; Garima Gupta; Paul J Kim Journal: Endocr Pract Date: 2007 Jul-Aug Impact factor: 3.443
Authors: Renato Bandeira de Mello; Karina Giassi; Gabriela Stahl; Maria Luisa Machado Assis; Marina Siqueira Flores; Bruna Cambrussi de Lima; Vanessa Piccoli; Ticiana da Costa Rodrigues Journal: Front Med (Lausanne) Date: 2022-06-23
Authors: João Paulo Vilela Rodrigues; Fabiana Angelo Marques; Ana Maria Rosa Freato Gonçalves; Marília Silveira de Almeida Campos; Tiago Marques Dos Reis; Manuela Roque Siani Morelo; Andrea Fontoura; Beatriz Maria Pereira Girolineto; Helen Palmira Miranda de Camargo Souza; Maurílio de Souza Cazarim; Lauro César da Silva Maduro; Leonardo Régis Leira Pereira Journal: PLoS One Date: 2019-01-18 Impact factor: 3.240